Eli Lilly shares tumble over 10% after disappointing weight-loss pill data

Lilly’s results from an obesity pill study didn’t perform as well as Wall Street expected. It resulted in lower weight loss and higher rates of nausea and vomiting than anticipated, side effects associated with so-called GLP-1 drugs